CoreCap Advisors LLC purchased a new position in InMode Ltd. (NASDAQ:INMD – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,050 shares of the healthcare company’s stock, valued at approximately $37,000.
A number of other large investors also recently modified their holdings of the business. Belpointe Asset Management LLC bought a new stake in InMode in the fourth quarter worth about $37,000. Parallel Advisors LLC boosted its position in InMode by 9,263.6% during the fourth quarter. Parallel Advisors LLC now owns 1,030 shares of the healthcare company’s stock valued at $37,000 after purchasing an additional 1,019 shares during the last quarter. Brown Brothers Harriman & Co. bought a new position in InMode during the first quarter valued at approximately $41,000. Toth Financial Advisory Corp lifted its position in shares of InMode by 80.0% in the fourth quarter. Toth Financial Advisory Corp now owns 1,350 shares of the healthcare company’s stock worth $48,000 after buying an additional 600 shares during the last quarter. Finally, Knuff & Co LLC boosted its position in InMode by 44.4% during the fourth quarter. Knuff & Co LLC now owns 1,625 shares of the healthcare company’s stock worth $58,000 after purchasing an additional 500 shares during the period. 55.24% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Needham & Company LLC downgraded shares of InMode from a “buy” rating to a “hold” rating in a report on Friday, February 17th. Barclays boosted their price objective on InMode from $45.00 to $47.00 in a research note on Thursday, May 4th. UBS Group started coverage on shares of InMode in a research note on Tuesday, March 28th. They set a “buy” rating and a $40.00 price target on the stock. Finally, TheStreet upgraded shares of InMode from a “c+” rating to a “b-” rating in a research report on Wednesday, April 19th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.71.
InMode Stock Performance
About InMode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Stories
- Get a free copy of the StockNews.com research report on InMode (INMD)
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
- Salesforce: Time to Snap it Up as the Market Buys the Dip?
Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMD – Get Rating).
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.
